^
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
BNT111 Sensitive: A1 - Approval
BioNTech Press Release - 1 week
|
BNT111 Sensitive: A1 - Approval
BioNTech Press Release - 1 week
|
BRAF mutation
|
Melanoma
|
BRAF mutation
|
Melanoma
|
PD1 inhibitor + BRAF inhibitor Sensitive: C3 – Early Trials
BMC Cancer - 2 weeks
|
PD1 inhibitor + BRAF inhibitor Sensitive: C3 – Early Trials
BMC Cancer - 2 weeks
|
BRAF mutation
|
Melanoma
|
BRAF mutation
|
Melanoma
|
PD1 inhibitor + BRAF inhibitor + MEK inhibitor Sensitive: C3 – Early Trials
BMC Cancer - 2 weeks
|
PD1 inhibitor + BRAF inhibitor + MEK inhibitor Sensitive: C3 – Early Trials
BMC Cancer - 2 weeks
|
NLRP3 mutation
|
Melanoma
|
NLRP3 mutation
|
Melanoma
|
Immunotherapy Sensitive: C3 – Early Trials
Aging (Albany NY) - 2 weeks
|
Immunotherapy Sensitive: C3 – Early Trials
Aging (Albany NY) - 2 weeks
|
GDF15-L
|
Melanoma
|
GDF15-L
|
Melanoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
SITC 2021 - 2 weeks
|
PD1 inhibitor Sensitive: C3 – Early Trials
SITC 2021 - 2 weeks
|
PD-L1-H + CXCL10-H + TNFA-H
|
Melanoma
|
PD-L1-H + CXCL10-H + TNFA-H
|
Melanoma
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
SITC 2021 - 2 weeks
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
SITC 2021 - 2 weeks
|
IFIT3 overexpression
|
Cutaneous Melanoma
|
IFIT3 overexpression
|
Cutaneous Melanoma
|
dasatinib Sensitive: C3 – Early Trials
Int Immunopharmacol - 2 weeks
|
dasatinib Sensitive: C3 – Early Trials
Int Immunopharmacol - 2 weeks
|
IFIT1 overexpression
|
Cutaneous Melanoma
|
IFIT1 overexpression
|
Cutaneous Melanoma
|
dasatinib Sensitive: C3 – Early Trials
Int Immunopharmacol - 2 weeks
|
dasatinib Sensitive: C3 – Early Trials
Int Immunopharmacol - 2 weeks
|
No biomarker
|
BCC
|
No biomarker
|
BCC
|
cemiplimab Sensitive: A1 - Approval
Sanofi Press Release - 4 weeks
|
cemiplimab Sensitive: A1 - Approval
Sanofi Press Release - 4 weeks
|
No biomarker
|
BCC
|
No biomarker
|
BCC
|
fluorouracil topical Sensitive: A1 - Approval
|
fluorouracil topical Sensitive: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
vemurafenib + atezolizumab + cobimetinib Sensitive: A1 - Approval
|
vemurafenib + atezolizumab + cobimetinib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
dabrafenib Sensitive: A1 - Approval
|
dabrafenib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
BRAF V600K
|
Melanoma
|
BRAF V600K
|
Melanoma
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
vemurafenib Sensitive: A1 - Approval
|
vemurafenib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
trametinib Sensitive: A1 - Approval
|
trametinib Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
BCC
|
No biomarker
|
BCC
|
vismodegib Sensitive: A1 - Approval
|
vismodegib Sensitive: A1 - Approval
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
avelumab Sensitive: A1 - Approval
|
avelumab Sensitive: A1 - Approval
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
BCC
|
No biomarker
|
BCC
|
imiquimod Sensitive: A1 - Approval
|
imiquimod Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
ipilimumab Sensitive: A1 - Approval
|
ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
PD-L1 underexpression
|
Melanoma
|
PD-L1 underexpression
|
Melanoma
|
ipilimumab Sensitive: A1 - Approval
|
ipilimumab Sensitive: A1 - Approval
|
PD-L1 underexpression
|
Melanoma
|
PD-L1 underexpression
|
Melanoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
dabrafenib Sensitive: A1 - Approval
|
dabrafenib Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
trametinib Resistant: A1 - Approval
|
trametinib Resistant: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
trametinib Sensitive: A1 - Approval
|
trametinib Sensitive: A1 - Approval
|
BRAF V600K
|
Melanoma
|
BRAF V600K
|
Melanoma
|
trametinib Sensitive: A1 - Approval
|
trametinib Sensitive: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
vemurafenib Sensitive: A1 - Approval
|
vemurafenib Sensitive: A1 - Approval
|
No biomarker
|
BCC
|
No biomarker
|
BCC
|
sonidegib Sensitive: A1 - Approval
|
sonidegib Sensitive: A1 - Approval
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
ipilimumab Sensitive: A1 - Approval
|
ipilimumab Sensitive: A1 - Approval
|
BRAF V600K
|
Melanoma
|
BRAF V600K
|
Melanoma
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
BRAF V600K
|
Melanoma
|
BRAF V600K
|
Melanoma
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
LDH elevation
|
Melanoma
|
LDH elevation
|
Melanoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
aldesleukin Sensitive: A1 - Approval
|
aldesleukin Sensitive: A1 - Approval
|
No biomarker
|
BCC
|
No biomarker
|
BCC
|
celecoxib Resistant: A2 - Guideline
|
celecoxib Resistant: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
TC Sensitive: A2 - Guideline
|
TC Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
TC Sensitive: A2 - Guideline
|
TC Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
ipilimumab Sensitive: A2 - Guideline
|
ipilimumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
dacarbazine Sensitive: A2 - Guideline
|
dacarbazine Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
trametinib Resistant: A2 - Guideline
|
trametinib Resistant: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
vemurafenib + atezolizumab + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + atezolizumab + cobimetinib Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
dacarbazine Sensitive: A2 - Guideline
|
dacarbazine Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
BRAF mutation
|
Melanoma
|
BRAF mutation
|
Melanoma
|
dabrafenib + granisetron intravenous Sensitive: A2 - Guideline
|
dabrafenib + granisetron intravenous Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
NRAS mutation
|
Melanoma
|
NRAS mutation
|
Melanoma
|
binimetinib Sensitive: A2 - Guideline
|
binimetinib Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
binimetinib + encorafenib Sensitive: A2 - Guideline
|
binimetinib + encorafenib Sensitive: A2 - Guideline
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
BRAF inhibitor + MEK inhibitor Sensitive: A2 - Guideline
|
BRAF inhibitor + MEK inhibitor Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
carboplatin + etoposide oral Sensitive: A2 - Guideline
|
carboplatin + etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
topotecan Sensitive: A2 - Guideline
|
topotecan Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Melanoma
|
NTRK1 fusion
|
Melanoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Melanoma
|
NTRK3 fusion
|
Melanoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Melanoma
|
NTRK2 fusion
|
Melanoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
dabrafenib + SNR1611 Sensitive: A2 - Guideline
|
dabrafenib + SNR1611 Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
BRAF V600K
|
Cutaneous Melanoma
|
BRAF V600K
|
Cutaneous Melanoma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
BRAF V600K
|
Cutaneous Melanoma
|
BRAF V600K
|
Cutaneous Melanoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
BRAF V600K
|
Cutaneous Melanoma
|
BRAF V600K
|
Cutaneous Melanoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
ROS1 fusion
|
Melanoma
|
ROS1 fusion
|
Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
KIT exon 11 mutation
|
Melanoma
|
KIT exon 11 mutation
|
Melanoma
|
sunitinib Sensitive: A2 - Guideline
|
sunitinib Sensitive: A2 - Guideline
|
KIT exon 11 mutation
|
Melanoma
|
KIT exon 11 mutation
|
Melanoma
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
KIT exon 13 mutation
|
Melanoma
|
KIT exon 13 mutation
|
Melanoma
|
sunitinib Sensitive: A2 - Guideline
|
sunitinib Sensitive: A2 - Guideline
|
BRAF V600K
|
Melanoma
|
BRAF V600K
|
Melanoma
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
TMB-H
|
Melanoma
|
TMB-H
|
Melanoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
ROS1 fusion
|
Melanoma
|
ROS1 fusion
|
Melanoma
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Melanoma
|
NTRK3 fusion
|
Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Melanoma
|
NTRK1 fusion
|
Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
KIT exon 13 mutation
|
Melanoma
|
KIT exon 13 mutation
|
Melanoma
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
BRAF fusion
|
Melanoma
|
BRAF fusion
|
Melanoma
|
sorafenib Sensitive: A2 - Guideline
|
sorafenib Sensitive: A2 - Guideline
|
ALK fusion
|
Melanoma
|
ALK fusion
|
Melanoma
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
ALK fusion
|
Melanoma
|
ALK fusion
|
Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
pembrolizumab + dabrafenib Sensitive: A2 - Guideline
|
pembrolizumab + dabrafenib Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
talimogene laherparepvec Sensitive: A2 - Guideline
|
talimogene laherparepvec Sensitive: A2 - Guideline
|
